Browsing by Author "Schaaf, H. S."

Now showing 1 - 8 of 8
  • Thumbnail Image
    Item
    Bacille Calmette-Guerin (BCG) vaccine and the COVID-19 pandemic : responsible stewardship is needed
    (The Union, 2020) Schaaf, H. S.; Du Preez, K.; Kruger, M.; Solomons, R.; Taljaard, J. J.; Rabie, H.; Seddon, J. A.; Cotton, M. F.; Tebruegge, M.; Curtis, N.; Hesseling, A. C.
    We believe that responsible stewardship of the bacille Calmette-Guérin (BCG) vaccine in the context of the COVID-19 epidemic is urgently needed. Live attenuated BCG is currently the only licensed vaccine to protect against tuberculosis (TB). Neonatal BCG vaccination has proven efficacy in protecting infants and young children against life-threatening disseminated forms of TB, including TB meningitis and miliary TB.
  • Thumbnail Image
    Item
    Closing the reporting gap for childhood tuberculosis in South Africa : improving hospital referrals and linkages
    (IUATLD -- International Union Against Tuberculosis and Lung Disease, 2020-03-21) Du Preez, K.; Schaaf, H. S.; Dunbar, R.; Swartz, A.; Naidoo, P.; Hesseling, A. C.
    Setting: A referral hospital in Cape Town, Western Cape Province, Republic of South Africa. Objective: To measure the impact of a hospital-based referral service (intervention) to reduce initial loss to follow-up among children with tuberculosis (TB) and ensure the completeness of routine TB surveillance data. Design: A dedicated TB referral service was established in the paediatric wards at Tygerberg Hospital, Cape Town, in 2012. Allocated personnel provided TB education and counselling, TB referral support and weekly telephonic follow-up after hospital discharge. All children identified with TB were matched to electronic TB treatment registers (ETR.Net/EDRWeb). Multivariable logistic regression was used to compare reporting of culture-confirmed and drug-susceptible TB cases before (2007–2009) and during (2012) the intervention. Results: Successful referral with linkage to care was confirmed in 267/272 (98%) and successful reporting in 227/272 (84%) children. Children with drug-susceptible, culture-confirmed TB were significantly more likely to be reported during the intervention period than in the pre-intervention period (OR 2.52, 95%CI 1.33–4.77). The intervention effect remained consistent in multivariable analysis (adjusted OR 2.62; 95%CI 1.31–5.25) after adjusting for age, sex, human immunodeficiency virus status and the presence of TB meningitis. Conclusions: A simple hospital-based TB referral service can reduce initial loss to follow-up and improve recording and reporting of childhood TB in settings with decentralised TB services.
  • Thumbnail Image
    Item
    Decentralised care for child contacts of multidrug-resistant tuberculosis
    (The Union, 2012-09-21) Seddon, J. A.; Hesseling, A. C.; Dunbar, R.; Cox, H.; Hughes, J.; Fielding, K.; Godfrey-Faussett, P.; Schaaf, H. S.
    SETTING: Cape Town, South Africa. OBJECTIVE: To determine the number of multidrug-resistant tuberculosis (MDR-TB) child contacts routinely identified by health services, and whether a model of decentralised care improves access. METHODS: All MDR-TB source cases registered in Cape Town from April 2010 to March 2011 were included. All child contacts assessed at hospital and outreach clinics were recorded from May 2010 to June 2011. Electronic probabilistic matching was used to match source cases with potential child contacts; the number of children accessing decentralised (Khayelitsha) and hospital-based care was compared. RESULTS: Of 1221 MDR-TB source cases identified, 189 (15.5%) were registered in Khayelitsha; 31 (16.4%) had at least one child contact assessed. In contrast, 95 (9.2%) of the 1032 source cases diagnosed in the other Cape Town subdistricts (hospital-based care) had at least one child contact assessed (P = 0.003). Children in Khayelitsha were seen at a median of 71 days (interquartile range [IQR] 37–121 days) after source case diagnosis compared to 90 days (IQR 56–132 days) in other subdistricts (P = 0.15). CONCLUSION: Although decentralised care led to an increased number of child contacts being evaluated, both models led to the assessment of a small number of potential child MDR-TB contacts, with considerable delay in assessment.
  • Thumbnail Image
    Item
    Global shortages of BCG vaccine and tuberculous meningitis in children
    (Elsevier, 2019) Du Preez, K.; Seddon, J. A.; Schaaf, H. S.; Hesseling, A. C.; Starke, J. R.; Osman, M.; Lombard, C. J.; Solomons, R.
    ENGLISH ABSTRACT: No abstract available.
  • Thumbnail Image
    Item
    Implementing novel regimens for drug-resistant TB in South Africa : what can the world learn?
    (International Union Against Tuberculosis and Lung Disease, 2020-10) Ndjeka, N.; Hughes, J.; Reuter, A.; Conradie, F.; Enwerem, M.; Ferreira, H.; Ismail, N.; Kock, Y.; Master, I.; Meintjes, G.; Padanilam, X.; Romero, R.; Schaaf, H. S.; te Riele, J.; Maartens, G.
    Worldwide uptake of new drugs in the treatment of rifampicin-resistant tuberculosis (RR-TB) has been extremely low. In June 2018, ahead of the release of the updated WHO guidelines for the management of RR-TB, South Africa announced that bedaquiline (BDQ) would be provided to virtually all RR-TB patients on shorter or longer regimens. South Africa has been the global leader in accessing BDQ for patients with RR-TB, who now represent 60% of the global BDQ cohort. The use of BDQ within a shorter modified regimen has generated the programmatic data underpinning the most recent change in WHO guidelines endorsing a shorter, injectable-free regimen. Progressive policies on access to new drugs have resulted in improved favourable outcomes and a reduction in mortality among RR-TB patients in South Africa. This supported global policy change. The strategies underpinning these bold actions include close collaboration between the South African National TB Programme and partners, introduction of new TB diagnostic tools in closely monitored conditions and the use of locally generated programmatic evidence to inform country policy changes. In this paper, we summarise a decade´s work that led to the bold decision to use a modified, short, injectable-free regimen with BDQ and linezolid under carefully monitored programmatic conditions.
  • Thumbnail Image
    Item
    Resistance to pyrazinamide and ethambutol compromises MDR/XDR-TB treatment
    (Health and Medical Publishing Group (HMPG), 2009-11) Hoek, K. G. P.; Schaaf, H. S.; Gey van Pittius, N. C.; Van Helden, P. D.; Warren, R. M.
  • Thumbnail Image
    Item
    Tuberculosis transmission in a hospitalised neonate : need for optimised tuberculosis screening of pregnant and postpartum women
    (Health & Medical Publishing Group, 2019) Zenhausern, J.; Bekker, A.; Wates, M. A.; Schaaf, H. S.; Dramowski, A.
    ENGLISH ABSTRACT: A recent fatal case of confirmed nosocomial tuberculosis (TB) transmission to a neonate in a kangaroo mother care (KMC) unit highlighted the infection risk to hospitalised neonates in South Africa, a high-burden TB setting. The index case was a 9-week-old infant who presented to another hospital’s intensive care unit with severe respiratory distress shortly after discharge from the KMC unit. Contact tracing identified that the infant had been exposed to a postpartum woman with undiagnosed pulmonary TB while in the KMC unit. Molecular testing confirmed nosocomial transmission between the index case and the presumed source case in the KMC unit. We describe the subsequent process of tracing other TB-exposed infants and mothers, the difficulty in confirming TB infection/disease in pregnancy, and the provision of isoniazid preventive therapy in this cohort. We discuss the practical implementation of TB screening approaches in maternity and neonatal wards in high-burden TB settings.
  • Thumbnail Image
    Item
    Why do child contacts of multidrug-resistant tuberculosis not come to the assessment clinic?
    (2012) Zimri, K.; Hesseling, A. C.; Godfrey-Faussett, P.; Schaaf, H. S.; Seddon, J. A.
    BACKGROUND: Local policy advises that children exposed to multidrug-resistant tuberculosis (MDR-TB) should be assessed in a specialist clinic. Many children, however, are not brought for assessment. METHODS: Focus group discussion was used to design appropriate questionnaires. From 1 September 2011, the first 50 children referred to the specialist paediatric MDR-TB clinic, Cape Town, South Africa, and who attended their clinic appointment, were recruited. The first 50 children who were referred but who did not attend were concurrently identified, traced and recruited. Differences in group characteristics were compared. RESULTS: The median age of the children was 35 months: 48 (48%) were boys, 4 (4%) were human immunodeficiency virus infected and 47 (47%) were of coloured ethnicity. Factors significantly associated with non-attendance at the MDR-TB clinic were: Coloured ethnicity (OR 2.82, 95%CI 1.21–6.59, P = 0.01), the mother being the source case (OR 3.78, 95%CI 1.29–11.1, P = 0.02), having a smoker resident in the house (OR 2.37, 95%CI 1.01–5.57, P = 0.04), the time (P = 0.002) and cost (P = 0.03) required to get to the specialist clinic, and fear of infection whilst waiting to be seen (OR 2.45, 95%CI 1.07–5.60, P = 0.03). CONCLUSIONS: Reasons for non-attendance at paediatric MDR-TB clinic appointments are complex and are influenced by demographic, social, logistical and cultural factors.